ABSTRACT
The purpose of this study is to compare conventional start in early follicular phase (EFP) with late follicular phase (LFP) and luteal phase (LP) in controlled ovarian stimulation (COS) for fertility preservation (FP) to assess differences in clinical outcomes. Retrospective study of the first cycles of COS for FP in oncological patients between 2012 and 2020 in a tertiary hospital. Two-hundred forty-eight cycles were classified into 3 groups: 176 cycles in EFP, 8 cycles in LFP, and 52 cycles in LP. Comparing LFP to EFP, there were no differences in number of oocytes (10.0 [6.3-16.0] vs 12.0 [8.0-18.0]; p = 0.253) or number of metaphase II (MII) obtained (7.0 [2.3-13.3] vs 9.0 [6.0-13.0]; p = 0.229). Total number of days needed was higher in LFP (14.5 [12.5-16.0] vs 3.0 vs 10.0 [8.3-11.0 p = 0.000) but without significant differences in number of days of usage of gonadotropins (11.5 [8.3-12.8] vs 10.0 [8.3-11.0] p = 0.308). No differences were found between LP and EFP in number of oocytes (14.5 [9.0-20.0] p = 0.151) or MII (11.5 [7.0-16.0] p = 0.084). Number of days of gonadotropins (11.0 [10.0-12.0] p = 0.00) and total dosing (3000.0 [2475.0-3600.0] p = 0.013) were significantly higher in LP. FORT and FOI were similar in all groups. COS with a random start in fertility preservation has similar outcomes to EFP start. Therefore, we can initiate COS at any phase of the menstrual cycle with optimal results. However, LP may need more days of stimulation.
Subject(s)
Fertility Preservation , Female , Animals , Fertility Preservation/methods , Retrospective Studies , Menstrual Cycle , Gonadotropins , Ovulation Induction/methods , CryopreservationABSTRACT
The genetic dynamics of wild populations with releases of farm-reared reinforcements are very complex. These releases can endanger wild populations through genetic swamping or by displacing them. We assessed the genomic differences between wild and farm-reared red-legged partridges (Alectoris rufa) and described differential selection signals between both populations. We sequenced the whole genome of 30 wild and 30 farm-reared partridges. Both partridges had similar nucleotide diversity (π). Farm-reared partridges had a more negative Tajima's D and more and longer regions of extended haplotype homozygosity than wild partridges. We observed higher inbreeding coefficients (FIS and FROH) in wild partridges. Selective sweeps (Rsb) were enriched with genes that contribute to the reproductive, skin and feather colouring, and behavioural differences between wild and farm-reared partridges. The analysis of genomic diversity should inform future decisions for the preservation of wild populations.
Subject(s)
Galliformes , Animals , Farms , Galliformes/genetics , Skin , GenomicsABSTRACT
OBJECTIVE: To study the clinico-radiological paradox in multiple sclerosis (MS) relapse by analyzing the number and location of gadolinium-enhanced (Gd+) lesions on brain MRI before methylprednisolone (MP) treatment. METHODS: We analyzed brain MRI from 90 relapsed MS patients in two Phase IV multicenter double-blind randomized clinical trials that showed the noninferiority of different routes and doses of MP administration. A 1.5- or 3-T brain MRI was performed at baseline before MP treatment and within 15 days of symptom onset. The number and location of Gd+ lesions were analyzed. Associations were studied using univariate analysis. RESULTS: Sixty-two percent of patients had at least 1 Gd+ brain lesion; the median number was 1 (interquartile range 0-4), and 41% of patients had 2 or more lesions. The most frequent location of Gd+ lesions was subcortical (41.4%). Gd+ brain lesions were found in 71.4% of patients with brainstem-cerebellum symptoms, 57.1% with spinal cord symptoms and 55.5% with optic neuritis (ON). Thirty percent of patients with brain symptoms did not have Gd+ lesions, and only 43.6% of patients had symptomatic Gd+ lesions. The univariate analysis showed a negative correlation between age and the number of Gd+ lesions (p=0.002). CONCLUSION: Most patients with relapse showed several Gd+ lesions on brain MRI, even when the clinical manifestation was outside of the brain. Our findings illustrate the clinico-radiological paradox in MS relapse and support the value of brain MRI in this scenario.
Subject(s)
Gadolinium , Multiple Sclerosis , Brain/diagnostic imaging , Brain/pathology , Gadolinium/therapeutic use , Humans , Magnetic Resonance Imaging , Methylprednisolone/therapeutic use , Multiple Sclerosis/diagnostic imaging , Multiple Sclerosis/drug therapy , RecurrenceABSTRACT
Objective: To study the clinico-radiological paradox in multiple sclerosis (MS) relapse by analyzing the number and location of gadolinium-enhanced (Gd+) lesions on brain MRI before methylprednisolone (MP) treatment. Methods: We analyzed brain MRI from 90 relapsed MS patients in two Phase IV multicenter double-blind randomized clinical trials that showed the noninferiority of different routes and doses of MP administration. A 1.5- or 3-T brain MRI was performed at baseline before MP treatment and within 15 days of symptom onset. The number and location of Gd+ lesions were analyzed. Associations were studied using univariate analysis. Results: Sixty-two percent of patients had at least 1 Gd+ brain lesion; the median number was 1 (interquartile range 04), and 41% of patients had 2 or more lesions. The most frequent location of Gd+ lesions was subcortical (41.4%). Gd+ brain lesions were found in 71.4% of patients with brainstem-cerebellum symptoms, 57.1% with spinal cord symptoms and 55.5% with optic neuritis (ON). Thirty percent of patients with brain symptoms did not have Gd+ lesions, and only 43.6% of patients had symptomatic Gd+ lesions. The univariate analysis showed a negative correlation between age and the number of Gd+ lesions (p = 0.002). Conclusion: Most patients with relapse showed several Gd+ lesions on brain MRI, even when the clinical manifestation was outside of the brain. Our findings illustrate the clinico-radiological paradox in MS relapse and support the value of brain MRI in this scenario. (AU)
Objetivo: Estudiar la paradoja clínico-radiológica en el brote de la esclerosis múltiple (EM) mediante el análisis de lesiones captantes de gadolinio (Gd+) en la RM cerebral antes del tratamiento con metilprednisolona (MP). Métodos: Analizamos la RM cerebral basal de 90 pacientes con EM en brote de 2 ensayos clínicos aleatorizados multicéntricos fase IV que demostraron la no inferioridad de diferentes vías y dosis de MP, realizadas antes del tratamiento con MP y en los 15 días siguientes a la aparición de los síntomas. Se analizaron el número y la localización de las lesiones Gd+. Se estudiaron las asociaciones mediante análisis univariado. Resultados: El 62% de los pacientes tenía al menos una lesión Gd+ cerebral y el 41% de los pacientes tenía 2 o más lesiones. La localización más frecuente fue la subcortical (41,4%). Se encontraron lesiones Gd+ cerebrales en el 71,4% de los pacientes con síntomas de tronco cerebral o cerebelo, en el 57,1% con síntomas medulares y en el 55,5% con neuritis óptica. El 30% de los pacientes con síntomas cerebrales no tenían lesiones Gd+ y sólo el 4,.6% de los pacientes tenían lesiones Gd+ sintomáticas. El análisis univariante mostró una correlación negativa entre la edad y el número de lesiones Gd+ (p = 0,002). Conclusiones: La mayoría de los pacientes en brote mostraron varias lesiones Gd+ en la RM cerebral, incluso cuando la manifestación clínica fue medular u óptica. Nuestros hallazgos ilustran la paradoja clínico-radiológica en el brote de la EM y apoyan el valor de la RM cerebral en este escenario. (AU)
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Multiple Sclerosis , Seedlings , Magnetic Resonance Spectroscopy , Gadolinium , Brain InjuriesABSTRACT
Our aim was to evaluate whether fatty liver index (FLI) is associated with the risk of type 2 diabetes (T2DM) development within the Spanish adult population and according to their prediabetes status; additionally, to examine its incremental predictive value regarding traditional risk factors. A total of 2260 subjects (Prediabetes: 641 subjects, normoglycemia: 1619 subjects) from the Di@bet.es cohort study were studied. Socio-demographic, anthropometric, clinical data and survey on habits were recorded. An oral glucose tolerance test was performed and fasting determinations of glucose, lipids and insulin were made. FLI was calculated and classified into three categories: Low (< 30), intermediate (30-60) and high (> 60). In total, 143 people developed diabetes at follow-up. The presence of a high FLI category was in all cases a significant independent risk factor for the development of diabetes. The inclusion of FLI categories in prediction models based on different conventional T2DM risk factors significantly increase the prediction power of the models when all the population was considered. According to our results, FLI might be considered an early indicator of T2DM development even under normoglycemic condition. The data also suggest that FLI could provide additional information for the prediction of T2DM in models based on conventional risk factors.
Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Type 2/complications , Non-alcoholic Fatty Liver Disease/complications , Adult , Biomarkers/metabolism , Cohort Studies , Female , Humans , Male , Middle AgedABSTRACT
OBJECTIVES: The aim of the study was to investigate the dynamics of cytomegalovirus (CMV) replication and CMV-specific immune response recovery after antiretroviral treatment (ART) initiation in patients with advanced HIV infection. METHODS: A prospective observational study of patients with HIV infection and CD4 counts of < 100 cells/µL was carried out (September 2015 to July 2018). HIV viral load (VL), CD4 count and CMV VL were determined by quantitative polymerase chain reaction (PCR) at baseline and at 4, 12, 24 and 48 weeks, and CMV-specific immune response was determined by QuantiFERON-CMV assay at baseline and 48 weeks. All patients were started on ART but only those with CMV end-organ disease (EOD) received anti-CMV treatment. RESULTS: Fifty-three patients with a median age of 43.6 [interquartile range (IQR) 36.7-52.4] years were included in the study. At baseline, the median CD4 count was 30 cells/µL (IQR 20-60 cells/µL) and the median HIV VL was 462 000 HIV-1 RNA copies/mL (IQR 186 000-1 300 000 copies/mL). At baseline, 32% patients had detectable CMV viraemia but none had detectable CMV viraemia at 48 weeks. Only one of 53 (1.9%) patients developed EOD during follow-up. Seven (13.2%) patients were lost to follow-up and six (11.3%) died; none of the deaths was related to CMV. Similar percentages of patients had a CMV-specific immune response at baseline (71.7%) and at 48 weeks (70.0%). The magnitude of this response tended to increase over time [median 1.63 (IQR 0.15-5.77) IU/mL at baseline vs. median 2.5 (IQR 0.1-8.325) IU/mL at 48 weeks; P = 0.11]. We did not find any risk factors associated with 48-week mortality. CONCLUSIONS: Although the prevalence of CMV viraemia in patients with advanced HIV infection remains high, achieving a good immunological recovery through ART is enough to suppress CMV viraemia, without an increased risk of CMV EOD. The prevalence of a CMV-specific immune response was high and endured over time.
Subject(s)
Cytomegalovirus Infections , HIV Infections , Adult , CD4 Lymphocyte Count , Cytomegalovirus , Cytomegalovirus Infections/epidemiology , Follow-Up Studies , HIV Infections/complications , HIV Infections/drug therapy , HIV Infections/epidemiology , Humans , Middle Aged , Prevalence , Viral Load , ViremiaABSTRACT
BACKGROUND: To estimate the potential benefits in terms of avoided complications and cost reduction if the Spanish health system would encourage the intensification of treatment for better glycaemic control in adults with Type 2 diabetes from the current HbA1c target used in clinical practice of 68 mmol/mol to a target of 53 mmol/mol. METHODS: The IQVIA Core Diabetes Model (version 9.0) was used to model the impact of these changes in respect of micro- and macrovascular complications and the associated costs. The modelling was based on data derived from the SIDIAP-Q population database from Catalonia, taking a random cohort of 10,000 people with type 2 diabetes and dividing it into sub-groups based on their baseline HbA1c. RESULTS: The CDM modelling showed that the average cost reduction per person varies depending on baseline HbA1c. The model estimates that after 25 years, people with a baseline HbA1c between 48 and 58 mmol/mol and > 75 mmol/mol show an average cost reduction of 6027 and 11,966, respectively. Applying the per-person cost reduction to the cohorts of the prevalent population in Spain (1,910,374) the overall estimated cost reduction was 14.7 billion over 25 years. The improvements in outcomes resulted in an estimated reduction of more than 1.2 million complications cumulatively over 25 years, of which more than 550,000 relate to diabetic foot and more than 170,000 related to renal disease. CONCLUSION: Over a 25 year period, Spain could considerably reduce costs and avoid major complications if, on a population level, more ambitious glycaemic control, according to Spanish or EU guidelines, could be achieved among people with type 2 diabetes by reducing the HbA1c threshold for treatment intensification. Although there is a slower trajectory for benefits in earlier years, there is a much more rapid benefit gain between years 5 and 15.
Subject(s)
Diabetes Mellitus, Type 2/therapy , Glycemic Control/statistics & numerical data , Primary Health Care , Aged , Cohort Studies , Costs and Cost Analysis/statistics & numerical data , Diabetes Complications/economics , Diabetes Complications/prevention & control , Female , Glycated Hemoglobin/analysis , Health Services Research , Humans , Male , Middle Aged , SpainABSTRACT
ANTECEDENTES Y OBJETIVOS: La diabetes supone un importante factor de riesgo para el desarrollo de enfermedad cardiovascular, principal causa de muerte. El propósito de este estudio fue conocer el grado de control glucémico de los pacientes con diabetes tipo 2 sin enfermedad cardiovascular en España, según la determinación más reciente de hemoglobina glucosilada, así como el patrón de tratamiento antidiabético, la incidencia de episodios de hipoglucemia grave en los últimos 6 meses y el grado de control de los factores de riesgo cardiovascular, en función del género. PACIENTES Y MÉTODOS: Estudio epidemiológico nacional, multicéntrico y transversal. Participaron 800 médicos asociados a la redGDPS. RESULTADOS: Se incluyeron 1.059 pacientes, 57% varones. Edad media: 62,7 años en varones vs. 65,2 en mujeres (p < 0,001). Evolución de la diabetes: 9,4±7,5 años. HbA1c media: 7,0% en varones vs. 7,1% en mujeres (p = 0,039). Objetivo de control <7%: 47,2%. En tratamiento con metformina: 65%; inhibidores DPP-4: 62,4%; insulina basal: 14,2%. Incidencia de hipoglucemias graves en los últimos 6 meses: 1,9%. Las mujeres presentaron peor control glucémico, colesterol total, colesterol LDL, obesidad abdominal y filtrado glomerular. CONCLUSIONES: El control glucémico es peor en las mujeres incluso si ajustamos por edad y tiempo de evolución de la diabetes (p = 0,043) y por el número de hipoglucemiantes (p = 0,015). El grado de control es también peor en mujeres para la dislipidemia, obesidad abdominal y filtrado glomerular. Desde Atención Primaria es esencial una estrategia preventiva promocionando estilos de vida saludables y controlando todos los factores de riesgo vascular
BACKGROUND AND OBJECTIVES: Diabetes is a significant risk factor for the development of cardiovascular disease, which is the main cause of death. The purpose of this study was to determine the level of glycaemic control in patients with type 2 diabetes without cardiovascular disease in Spain. The data used includes the most recent determination of glycosylated haemoglobin, as well as the pattern of antidiabetic treatment, the incidence of episodes of severe hypoglycaemia in the last 6 months, and the level of control of cardiovascular risk factors, and gender. PATIENTS AND METHODS: A national, multicentre, and cross-sectional epidemiological study in which 800 doctors associated with the GDPS network participated. RESULTS: Of the total of 1,059 patients, 57% male, with a mean age of 62.7 years in men vs. 65.2 in women (P<.001). The mean onset of diabetes was 9.4±7.5 years. The mean HbA1C was 7.0% in men vs. 7.1% in women (P=.039), with the control objective of <7% being observed in 47.2%. There were 65% patients on treatment with metformin, and 62.4% on DPP-4 inhibitors, and basal insulin: 14.2%. Incidence of severe hypoglycemias in the last 6 months was 1.9%. The women had worse glycaemic control, total cholesterol, LDL cholesterol, abdominal obesity, and glomerular filtration levels. CONCLUSIONS: The glycaemic control is worse in women even if adjusted for age and time of onset of diabetes (P=.043), and for the number of hypoglycaemic agents (P=.015). The level of control is also worse in women for dyslipidaemia, abdominal obesity, and glomerular filtration. A preventive strategy promoted from Primary care on healthy lifestyles and controlling all vascular risk factors is essential
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Diabetes Mellitus, Type 2/epidemiology , Hyperglycemia/prevention & control , Glycated Hemoglobin/analysis , Hypoglycemic Agents/therapeutic use , Glomerular Filtration Rate/drug effects , Cardiovascular Diseases/epidemiology , Spain/epidemiology , Risk Factors , Cross-Sectional Studies , Epidemiologic Studies , Obesity/complications , Age and Sex DistributionABSTRACT
INTRODUCCIÓN: Varios estudios han identificado un peor control de los factores de riesgo cardiovascular en el sexo femenino en pacientes con diabetes tipo 2. Una de sus causas podría ser el desconocimiento sobre el perfil de riesgo cardiovascular de la mujer con diabetes tipo 2 por parte de los profesionales. OBJETIVO: Conocer la percepción y el conocimiento de los profesionales de la salud involucrados en el manejo de los pacientes con diabetes tipo 2, del impacto que las diferencias de género tienen en el control de los factores de riesgo cardiovascular en estos pacientes. MÉTODO: Se envió una encuesta de 24 preguntas relacionadas con el conocimiento y percepción (agrupadas por temas) a profesionales interesados e involucrados en el cuidado de pacientes con diabetes tipo 2. Se analizaron 998 encuestas. Construimos un modelo de ANOVA para comparar los resultados por especialidad y años de experiencia ajustados por el resto de las variables de confusión y regresión logística para estudiar los factores que podían influir en tener más de 12 respuestas adecuadas (resultado favorable). RESULTADOS: La media de respuestas correctas fue 10,3, discretamente mayor para especialistas (rango 10,7-11,8) y aumentaba con la experiencia (p = 0,001). Se encontró el género femenino y los años de experiencia como predictores de tener 12 o más respuestas correctas. CONCLUSIONES: El nivel de conocimientos sobre el tema es bajo, pero similar a los resultados de otros estudios sobre la relación del género con determinadas patologías
INTRODUCTION: Several studies have found poorer control of the cardiovascular risk factors among women with type 2 diabetes. This could be explained by the lack of awareness of their cardiovascular risk among professionals. AIMS: To determine the perception and knowledge of health care professionals involved in diabetes management on the impact of gender difference on the control of cardiovascular risk factors in patients with type 2 diabetes mellitus. METHODS: A 24-question survey related to knowledge and perceptions (grouped by topics) was sent to professionals who were interested and involved in diabetes care. A total of 998 surveys were analysed. An ANOVA model was constructed to compare the results by specialty and years of experience, as well as adjusting for the rest of the confounding factors. On having more than 12 correct answers (favourable result), a logistic regression was also performed in order to study the factors that could have an influence. RESULTS: The mean number of correct answers was 10.3, and was slightly better for specialists (range 10.7-11.8), and associated with years of experience (P=.001). Female gender and years of experience were identified as predictors of having more than 12 correct answers. CONCLUSIONS: The level of knowledge was low, but similar to the results of the other studies
Subject(s)
Humans , Male , Female , Young Adult , Adult , Middle Aged , Cardiovascular Diseases/etiology , Diabetes Mellitus, Type 2/complications , Health Knowledge, Attitudes, Practice , Health Personnel/statistics & numerical data , Risk Factors , Sex Factors , Surveys and QuestionnairesABSTRACT
INTRODUCCIÓN Y OBJETIVOS: Con la implementación de la Estrategia de Promoción de la Salud y Prevención en España, el escenario reflejado en estudios previos de infracontrol de los factores de riesgo cardiovascular (FRCV) en pacientes con diabetes tipo 2 (DM2) y enfermedad cardiovascular (ECV) puede haberse modificado, por lo que nos planteamos conocer el grado de control glucémico y de otros FRCV en los pacientes con DM2 y ECV atendidos actualmente en nuestro medio, el patrón de tratamiento antidiabético y las diferencias en función del género. MATERIALES Y MÉTODOS: Estudio epidemiológico, observacional, transversal, de ámbito nacional en pacientes de ambos géneros diagnosticados de DM2 y ECV establecida. RESULTADOS: Se incluyeron 3.143 pacientes. Edad media: 69,0±10 años. La HbA1c media fue mayor en mujeres que en varones (7,4±1,1% vs. 7,3±1,2%; p < 0,05), así como el colesterol-LDL (101,5±38,1mg/dl vs. 91,1±37,5mg/dl; p < 0,001), la presión arterial sistólica (137,0mmHg vs. 135,6mmHg; p < 0,05) y el índice de masa corporal (30,7±5,4kg/m2 vs. 29,6±4,5kg/m2; p < 0,001). Los tratamientos más utilizados fueron la metformina (68,1%) y/o inhibidores-DPP4 (53,7%), sin diferencias entre géneros. CONCLUSIONES: El grado de control glucémico de los pacientes con DM2 y ECV en España es mejorable. El perfil de tratamiento no se ajusta a las recomendaciones de las guías de práctica clínica en general. Las diferencias en el control de los FRCV son peores en mujeres para lípidos y obesidad
INTRODUCTION AND OBJECTIVES: With the implementation of the Strategy of Health Promotion and Prevention in Spain, the scenario reflected in previous studies of low control of cardiovascular risk factors (CVRF) in patients with type 2 diabetes (DM2) and cardiovascular disease (CVD) can be modified. This study intends to determine the level of blood glucose control and other CVRF in patients with DM2 and CVD currently seen in clinics in Spain, as well as the pattern of antidiabetic treatment, and differences according to gender. MATERIALS AND METHODS: An epidemiological, observational, cross-sectional, nationwide study was conducted in patients of both genders diagnosed with DM2 and established CVD. RESULTS: The study included 3,143 patients with a mean age 69.0±10 years. The mean HbA1c was 7.4±1.1% in females vs 7.3±1.2% in males (P<.05) and systolic blood pressure was 137±15.0mmHg in females vs 135.6±14.7mmHg in males (P<.05). The mean LDL-cholesterol was 101.5±38.1mg/dl in females vs 91.1±37.5mg/dl in males; P<.001) and the mean body mass index (30.7±5.4kg/m2 in females vs 29.6±4.5kg/m2 in males; P<.001). The most used treatments were metformin (68.1%) and/or DPP4 inhibitors (53.7%), with no differences between genders. CONCLUSIONS: The level of blood glucose control of DM2 patients with CVD in Spain can be improved. The treatment profile does not conform to the recommendations of clinical practice guidelines in general. The differences in the control of CVRF are worse in women for lipids and obesity
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Cardiovascular Diseases/epidemiology , Diabetes Mellitus, Type 2/epidemiology , Hypoglycemic Agents/administration & dosage , Obesity/epidemiology , Arterial Pressure , Cross-Sectional Studies , Diabetes Mellitus, Type 2/drug therapy , Glycated Hemoglobin/metabolism , Lipids/blood , Sex Factors , SpainABSTRACT
Our aim was to determine the incidence of type 2 diabetes mellitus in a nation-wide population based cohort from Spain (di@bet.es study). The target was the Spanish population. In total 5072 people older than 18 years,were randomly selected from all over Spain). Socio-demographic and clinical data, survey on habits (physical activity and food consumption) and weight, height, waist, hip and blood pressure were recorder. A fasting blood draw and an oral glucose tolerance test were performed. Determinations of serum glucose were made. In the follow-up the same variables were collected and HbA1c was determined. A total of 2408 subjects participated in the follow-up. In total, 154 people developed diabetes (6.4% cumulative incidence in 7.5 years of follow-up). The incidence of diabetes adjusted for the structure of age and sex of the Spanish population was 11.6 cases/1000 person-years (IC95% = 11.1-12.1). The incidence of known diabetes was 3.7 cases/1000 person-years (IC95% = 2.8-4.6). The main risk factors for developing diabetes were the presence of prediabetes in cross-sectional study, age, male sex, obesity, central obesity, increase in weight, and family history of diabetes. This work provides data about population-based incidence rates of diabetes and associated risk factors in a nation-wide cohort of Spanish population.
Subject(s)
Cardiovascular Diseases/epidemiology , Diabetes Mellitus, Type 2/epidemiology , Obesity/epidemiology , Adult , Aged , Blood Glucose , Blood Pressure , Body Weight , Cardiovascular Diseases/blood , Cardiovascular Diseases/complications , Cardiovascular Diseases/pathology , Cohort Studies , Cross-Sectional Studies , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/pathology , Fasting , Female , Glucose Tolerance Test , Humans , Male , Middle Aged , Obesity/blood , Obesity/complications , Obesity/pathology , Risk Factors , Spain/epidemiologyABSTRACT
BACKGROUND AND OBJECTIVES: Diabetes is a significant risk factor for the development of cardiovascular disease, which is the main cause of death. The purpose of this study was to determine the level of glycaemic control in patients with type 2 diabetes without cardiovascular disease in Spain. The data used includes the most recent determination of glycosylated haemoglobin, as well as the pattern of antidiabetic treatment, the incidence of episodes of severe hypoglycaemia in the last 6 months, and the level of control of cardiovascular risk factors, and gender. PATIENTS AND METHODS: A national, multicentre, and cross-sectional epidemiological study in which 800 doctors associated with the GDPS network participated. RESULTS: Of the total of 1,059 patients, 57% male, with a mean age of 62.7 years in men vs. 65.2 in women (P<.001). The mean onset of diabetes was 9.4±7.5 years. The mean HbA1C was 7.0% in men vs. 7.1% in women (P=.039), with the control objective of <7% being observed in 47.2%. There were 65% patients on treatment with metformin, and 62.4% on DPP-4 inhibitors, and basal insulin: 14.2%. Incidence of severe hypoglycemias in the last 6 months was 1.9%. The women had worse glycaemic control, total cholesterol, LDL cholesterol, abdominal obesity, and glomerular filtration levels. CONCLUSIONS: The glycaemic control is worse in women even if adjusted for age and time of onset of diabetes (P=.043), and for the number of hypoglycaemic agents (P=.015). The level of control is also worse in women for dyslipidaemia, abdominal obesity, and glomerular filtration. A preventive strategy promoted from Primary care on healthy lifestyles and controlling all vascular risk factors is essential.
Subject(s)
Cardiovascular Diseases , Blood Glucose , Cross-Sectional Studies , Diabetes Mellitus, Type 2 , Female , Glycated Hemoglobin/analysis , Humans , Hypoglycemic Agents , Male , Middle Aged , SpainABSTRACT
INTRODUCTION: Several studies have found poorer control of the cardiovascular risk factors among women with type 2 diabetes. This could be explained by the lack of awareness of their cardiovascular risk among professionals. AIMS: To determine the perception and knowledge of health care professionals involved in diabetes management on the impact of gender difference on the control of cardiovascular risk factors in patients with type 2 diabetes mellitus. METHODS: A 24-question survey related to knowledge and perceptions (grouped by topics) was sent to professionals who were interested and involved in diabetes care. A total of 998 surveys were analysed. An ANOVA model was constructed to compare the results by specialty and years of experience, as well as adjusting for the rest of the confounding factors. On having more than 12 correct answers (favourable result), a logistic regression was also performed in order to study the factors that could have an influence. RESULTS: The mean number of correct answers was 10.3, and was slightly better for specialists (range 10.7-11.8), and associated with years of experience (P=.001). Female gender and years of experience were identified as predictors of having more than 12 correct answers. CONCLUSIONS: The level of knowledge was low, but similar to the results of the other studies.
Subject(s)
Cardiovascular Diseases/etiology , Diabetes Mellitus, Type 2/complications , Health Knowledge, Attitudes, Practice , Health Personnel/statistics & numerical data , Adult , Female , Humans , Male , Middle Aged , Risk Factors , Sex Factors , Surveys and Questionnaires , Young AdultABSTRACT
PURPOSE: Type 2 diabetes frequently remains undiagnosed for years, whereas early detection of affected individuals would facilitate the implementation of timely and cost-effective therapies, hence decreasing morbidity. With the intention of identifying novel diagnostic biomarkers, we characterized the miRNA profile of microvesicles isolated from retroactive serum samples of normoglycemic individuals and two groups of subjects with prediabetes that in the following 4 years either progressed to overt diabetes or remained stable. METHODS: We profiled miRNAs in serum microvesicles of a selected group of control and prediabetic individuals participating in the PREDAPS cohort study. Half of the subjects with prediabetes were diagnosed with diabetes during the 4 years of follow-up, while the glycemic status of the other half remained unchanged. RESULTS: We identified two miRNAs, miR-10b and miR-223-3p, which target components of the insulin signaling pathway and whose ratio discriminates between these two subgroups of prediabetic individuals at a stage at which other features, including glycemia, are less proficient at separating them. In global, the profile of miRNAs in microvesicles of prediabetic subjects primed to progress to overt diabetes was more similar to that of diabetic patients than the profile of prediabetic subjects who did not progress. CONCLUSION: We have identified a miRNA signature in serum microvesicles that can be used as a new screening biomarker to identify subjects with prediabetes at high risk of developing diabetes, hence allowing the implementation of earlier, and probably more effective, therapeutic interventions.
Subject(s)
Cell-Derived Microparticles/metabolism , Diabetes Mellitus, Type 2/blood , MicroRNAs/metabolism , Prediabetic State/blood , Aged , Biomarkers/blood , Blood Glucose/metabolism , Disease Progression , Female , Humans , Middle AgedABSTRACT
INTRODUCTION AND OBJECTIVES: With the implementation of the Strategy of Health Promotion and Prevention in Spain, the scenario reflected in previous studies of low control of cardiovascular risk factors (CVRF) in patients with type 2 diabetes (DM2) and cardiovascular disease (CVD) can be modified. This study intends to determine the level of blood glucose control and other CVRF in patients with DM2 and CVD currently seen in clinics in Spain, as well as the pattern of antidiabetic treatment, and differences according to gender. MATERIALS AND METHODS: An epidemiological, observational, cross-sectional, nationwide study was conducted in patients of both genders diagnosed with DM2 and established CVD. RESULTS: The study included 3,143 patients with a mean age 69.0±10 years. The mean HbA1c was 7.4±1.1% in females vs 7.3±1.2% in males (P<.05) and systolic blood pressure was 137±15.0mmHg in females vs 135.6±14.7mmHg in males (P<.05). The mean LDL-cholesterol was 101.5±38.1mg/dl in females vs 91.1±37.5mg/dl in males; P<.001) and the mean body mass index (30.7±5.4kg/m2 in females vs 29.6±4.5kg/m2 in males; P<.001). The most used treatments were metformin (68.1%) and/or DPP4 inhibitors (53.7%), with no differences between genders. CONCLUSIONS: The level of blood glucose control of DM2 patients with CVD in Spain can be improved. The treatment profile does not conform to the recommendations of clinical practice guidelines in general. The differences in the control of CVRF are worse in women for lipids and obesity.
Subject(s)
Cardiovascular Diseases/epidemiology , Diabetes Mellitus, Type 2/epidemiology , Glycemic Control , Hypoglycemic Agents/administration & dosage , Aged , Aged, 80 and over , Blood Pressure , Cross-Sectional Studies , Diabetes Mellitus, Type 2/drug therapy , Female , Glycated Hemoglobin/metabolism , Heart Disease Risk Factors , Humans , Lipids/blood , Male , Middle Aged , Obesity/epidemiology , Sex Factors , SpainSubject(s)
Fasciitis, Necrotizing/diagnosis , Orbital Diseases/diagnosis , Streptococcal Infections/diagnosis , Adult , Anti-Bacterial Agents/therapeutic use , Combined Modality Therapy , Debridement , Eye Infections, Bacterial/complications , Eye Infections, Bacterial/diagnosis , Eye Infections, Bacterial/therapy , Fasciitis, Necrotizing/microbiology , Fasciitis, Necrotizing/therapy , Female , Humans , Orbital Diseases/therapy , Streptococcal Infections/therapyABSTRACT
OBJECTIVE: The objective of this triple-blind, split-mouth, randomized clinical trial was to evaluate the bleaching efficacy and tooth sensitivity of an in-office bleaching agent submitted to different storage temperatures (room temperature at 21.04°C±3.13°C or refrigeration at 5°C). METHODS AND MATERIALS: Thirty volunteers were selected who had central incisors with color A2 or higher. The volunteers' maxillary hemi-arches received either the bleaching treatment with room temperature or refrigerated storage temperatures (two sessions of 3×15 minutes, one-week interval). Color variation was evaluated by subjective (Vita Classic and Vita Bleachedguide) and objective methods (Vita Easyshade spectrophotometer). Tooth sensitivity was evaluated with the visual analog scale (0-10) and the numerical rating scale (five points). The consistency of bleaching gels was evaluated by flow test, and pH was measured, both in triplicate. Color variation (SGU) and ΔE were analyzed by paired t-test (α=0.05). The absolute risk of pain was assessed by McNemar test (α=0.05), data from the numerical rating scale by the Wilcoxon signed-rank test (α=0.05), and visual analog scale by paired t-test. Comparison between the times within each group was analyzed by Friedman test. Gel consistency and pH were analyzed by one-way analysis of variance and Tukey post-test. RESULTS: Regarding the absolute risk of tooth sensitivity, no significant difference was observed between the groups. The relative risk for tooth sensitivity was 1.13 (95%, confidence interval 0.70-1.82). Both tooth sensitivity scales were statistically similar. The results of the subjective evaluation (Vita Classic: p=0.73, Vita Bleachedguide: p=1.00) and the objective evaluation (p=1.00) of bleaching efficacy corresponded to the hypothesis of equality between groups after bleaching. Both pH values were around 7, and for the consistency test, there were significant differences between the groups (p=0.002). CONCLUSIONS: Storage temperature of the analyzed in-office bleaching agent had no influence on tooth color effectiveness and tooth sensitivity.
Subject(s)
Dentin Sensitivity , Tooth Bleaching Agents , Tooth Bleaching , Color , Gels , Humans , Hydrogen Peroxide , Temperature , Treatment OutcomeABSTRACT
BACKGROUND AND PURPOSE: Oral or intravenous methylprednisolone (≥500 mg/day for 5 days) is recommended for multiple sclerosis (MS) relapses. Nonetheless, the optimal dose remains uncertain. We compared clinical and radiological effectiveness, safety and quality of life (QoL) of oral methylprednisolone [1250 mg/day (standard high dose)] versus 625 mg/day (lesser high dose), both for 3 days] in MS relapses. METHODS: A total of 49 patients with moderate to severe MS relapse within the previous 15 days were randomized in a pilot, double-blind, multicentre, non-inferiority trial (ClinicalTrial.gov, NCT01986998). The primary endpoint was non-inferiority of the lesser high dose by Expanded Disability Status Scale (EDSS) score improvement on day 30 (non-inferiority margin, 1 point). The secondary endpoints were EDSS score change on days 7 and 90, changes in T1 gadolinium-enhanced and new/enlarged T2 lesions on days 7 and 30, and safety and QoL results. RESULTS: The primary outcome was achieved [mean (95% confidence interval) EDSS score difference, -0.26 (-0.7 to 0.18) at 30 days (P = 0.246)]. The standard high dose yielded a superior EDSS score improvement on day 7 (P = 0.028). No differences were observed in EDSS score on day 90 (P = 0.352) or in the number of T1 gadolinium-enhanced or new/enlarged T2 lesions on day 7 (P = 0.401, 0.347) or day 30 (P = 0.349, 0.529). Safety and QoL were good at both doses. CONCLUSIONS: A lesser high-dose oral methylprednisolone regimen may not be inferior to the standard high dose in terms of clinical and radiological response.
Subject(s)
Glucocorticoids/administration & dosage , Methylprednisolone/administration & dosage , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Outcome Assessment, Health Care , Adult , Double-Blind Method , Equivalence Trials as Topic , Female , Humans , Male , Middle Aged , Pilot Projects , Quality of LifeABSTRACT
BACKGROUND: Prolonged breath holding results in hypoxemia and hypercapnia. Compensatory mechanisms help maintain adequate oxygen supply to hypoxia sensitive organs, but burden the cardiovascular system. The aim was to investigate human compensatory mechanisms and their effects on the cardiovascular system with regard to cardiac function and morphology, blood flow redistribution, serum biomarkers of the adrenergic system and myocardial injury markers following prolonged apnoea. METHODS: Seventeen elite apnoea divers performed maximal breath-hold during cardiovascular magnetic resonance imaging (CMR). Two breath-hold sessions were performed to assess (1) cardiac function, myocardial tissue properties and (2) blood flow. In between CMR sessions, a head MRI was performed for the assessment of signs of silent brain ischemia. Urine and blood samples were analysed prior to and up to 4 h after the first breath-hold. RESULTS: Mean breath-hold time was 297 ± 52 s. Left ventricular (LV) end-systolic, end-diastolic, and stroke volume increased significantly (p < 0.05). Peripheral oxygen saturation, LV ejection fraction, LV fractional shortening, and heart rate decreased significantly (p < 0.05). Blood distribution was diverted to cerebral regions with no significant changes in the descending aorta. Catecholamine levels, high-sensitivity cardiac troponin, and NT-pro-BNP levels increased significantly, but did not reach pathological levels. CONCLUSION: Compensatory effects of prolonged apnoea substantially burden the cardiovascular system. CMR tissue characterisation did not reveal acute myocardial injury, indicating that the resulting cardiovascular stress does not exceed compensatory physiological limits in healthy subjects. However, these compensatory mechanisms could overly tax those limits in subjects with pre-existing cardiac disease. For divers interested in competetive apnoea diving, a comprehensive medical exam with a special focus on the cardiovascular system may be warranted. TRIAL REGISTRATION: This prospective single-centre study was approved by the institutional ethics committee review board. It was retrospectively registered under ClinicalTrials.gov (Trial registration: NCT02280226 . Registered 29 October 2014).
Subject(s)
Apnea/diagnostic imaging , Breath Holding , Cardiovascular System/diagnostic imaging , Diving , Magnetic Resonance Imaging, Cine , Adaptation, Physiological , Adult , Apnea/blood , Apnea/physiopathology , Biomarkers/blood , Cardiovascular System/metabolism , Cardiovascular System/physiopathology , Diving/adverse effects , Epinephrine/blood , Female , Hemodynamics , Humans , Male , Middle Aged , Natriuretic Peptide, Brain/blood , Norepinephrine/blood , Peptide Fragments/blood , Predictive Value of Tests , Regional Blood Flow , Risk Factors , Time Factors , Troponin/blood , Ventricular Function, Left , Young AdultABSTRACT
No disponible